DESTINY-Breast09 & the Future of Care - Dr. Irene Kang & Dr. Aditya Bardia

Introducing The Breast Friends Podcast | Where Breast Cancer Science Meets Real Talk

Can T-DXd Change Early HER2+ Breast Cancer Forever? - Dr. Ruta Rao & Dr. VK Gadi

Induction to Maintenance: Is This the Future of ADCs in 1st line HER2+ mBC?

What Comes After DESTINY-Breast09?

Monitoring ILD with T-DXd: What Clinicians Need to Know

Dose Optimization: The Secret to Long-Term T-DXd Success

Managing Risk vs Benefit with T-DXd

Who Should Receive T-DXd First Line?

DESTINY-Breast09: Nearly 4 Years of PFS with T-DXd

Why First-Line Therapy Matters in HER2+ Metastatic Breast Cancer

Why the Curative Setting Changes the Risk–Benefit Equation

Managing ILD Risk & Radiation With Adjuvant T-DXd

DESTINY-Breast05 Explained: Can We Beat T-DM1?

Adaptive Neoadjuvant Therapy: Are We Ready Yet?

Residual Disease After Neoadjuvant Therapy: What Comes Next?

Is Anthracycline-Free Neoadjuvant Therapy Finally Here?

83% pCR: DESTINY-Breast11 Breaks the Neoadjuvant Ceiling

Should T-DXd Move Upfront in Early-Stage HER2+ Breast Cancer?

Why HER2 Status Alone Is No Longer Enough

What Happens After T-DXd? Sequencing Without a Playbook

What Comes After T-DXd in HER2+ Metastatic Breast Cancer?

Managing ILD With T-DXd: What Clinicians Need to Know

Choosing First-Line Therapy in HER2+ Metastatic Disease

The Frontline Face-Off: DB-09, PATINA, and HER2CLIMB-05

DESTINY-Breast09 Explained: Why 40 Months PFS Matters

Redefining the Horizon: Is Cure Possible in HER2+ mBC?

HER2+ Breast Cancer: The Most Transformed Disease in Oncology?

Eliminating the Surprise: Mapping the Path for Adjuvant Therapy After Surgery

Is pCR Enough? Why Regulators Still Want EFS Data

“Best Drug on Earth” Isn’t Enough If Patients Can’t Tolerate It

Does Higher pCR Come at a Cost? Weighing Efficacy vs Toxicity in DB-11

Beyond KATHERINE: The DB-05 Shift in High-Risk HER2+ Disease

The New 1st Line Reality in HER2+ mBC: Why the Strongest Tool Goes First

PATINA, HER2CLIMB-05 & the Maintenance Therapy Debate

Vigilance is Key: Managing ILD with T-DXd

The 1st Line Decision: Why T-DXd is Redefining the Start

Beyond CLEOPATRA: When the 1L Standard Falls Short

Cleopatra’s Survival Impact in HER2+ Metastatic Breast Cancer

Induction, Maintenance, or Both? Rethinking HER2+ mBC Treatment Strategy

The T-DXd Tradeoff: Balancing Breakthrough Efficacy with ILD Risk

Years on First-Line Therapy: A New Reality for Metastatic Breast Cancer

40-Month PFS: Why Destiny-Breast09 Is a Game Changer

Is It Time to Move Beyond Cleopatra in HER2+ Metastatic Breast Cancer?

After Frontline T-DXd: How Should HER2+ Disease Be Sequenced Next?

Maintenance or Maximum Response? Rethinking Long-Term Control in HER2+ Disease

Supportive Care with T-DXd: Antiemetics, Fatigue & Hair Preservation

Which HER2+ Patients Should Receive T-DXd + Pertuzumab First-Line?

Managing T-DXd Toxicity: ILD, Nausea, Fatigue & What to Watch For

Frontline HER2+ Therapy: Why “Best Drug First” May Matter More Than Sequencing

DESTINY-Breast09: 40-Month PFS — A New First-Line Reality for HER2+ Disease?

CLEOPATRA Explained: How It Became the First-Line Standard in HER2+ Breast Cancer

Dare We Say “Cure” in HER2 + Metastatic Breast Cancer?

Treating to Progression vs. Clinical Flexibility: Finding the Balance

Is T-DXd Worth the Risk? Evaluating Benefit vs Toxicity

Who Should Receive T-DXd + Pertuzumab in the First Line?

DESTINY-Breast09: 40 Months of PFS Changes Everything

Why CLEOPATRA Became the Gold Standard in HER2+ Metastatic Breast Cancer

Why Waiting for Second Line May Cost Patients Everything

PATINA & HER2CLIMB-05: Rethinking Maintenance Therapy